Alamandine (Ala), a lesser-known renin-angiotensin system heptapeptide acting via the MrgD receptor, reverses multiple hallmarks of intestinal aging in 22–24-month-old mice. Continuous Ala infusion via osmotic pumps reduced FITC-dextran intestinal permeability, restored Wnt3a/phospho-CREB/β-catenin signaling in colon organoids, increased gut microbiome richness and β-diversity while lowering the Bacillota/Bacteroidota ratio, shifted colonic macrophages from pro-inflammatory CD80+ to homeostatic CX3CR1+ phenotypes, and blocked aged cecal supernatant-driven myelopoiesis in bone marrow — reducing pro-inflammatory macrophage output.
The gut-bone marrow axis has emerged as a critical longevity node: a leaky gut floods the systemic circulation with microbial metabolites that chronically prime bone marrow toward inflammatory myeloid output, amplifying inflammaging. What makes this finding notable is the specificity of the MrgD receptor — distinct from the canonical ACE2/Mas axis — suggesting a targetable pathway that sidesteps systemic blood pressure effects. The mechanistic chain from a single peptide through ISC maintenance, microbiome remodeling, and BM reprogramming is ambitious and, if causal links hold, would be genuinely paradigm-adjacent. Limitations are significant: this is mouse-only, the oldest cohort represents extreme murine aging, and osmotic pump delivery has no direct human equivalent. Whether oral or injectable Ala formulations can replicate these effects in humans — and whether MrgD expression patterns translate — remains entirely untested. Incremental for now, but a compelling mechanistic framework worth watching.
